CytomX Therapeutics (CTMX) Tops Q1 EPS by 2c

CytomX Therapeutics (NASDAQ: CTMX) reported Q1 EPS of ($0.10), $0.02 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $10.26 million versus the consensus estimate of $4.64 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• BofA says convenience store sales trail broader retail channels
• iShares iBoxx $ High Yield Corporate Bond ETF (HYG) call put ratio 5.7 calls to 1 put with a focus on 50K contracts of September 50 calls
• iShares 20+ Year Treasury Bond ETF (TLT) call put ratio 1.3 calls to 1 put on 124K contracts